YuanSheng Venture Portfolio Companies—BoShengJi, China-US Huashitong, JunSai Bio, and Aikang Pharma—Named Among '2025 China Top 100 Emerging Pharmaceutical Innovators'
PersonGen
Developer of Tumor Cell Immunotherapy Technologies and Products
Juncell Therapeutics
Solid Tumor Cell Therapy Developer
ArkBio
Innovative Drug Developer
Click on the "blue words" above to follow more exciting content.
Recently, the 2025 China Pharma Innovation Seed Enterprises 100 (referred to as: Seed 100) list was released. This list isE Pharm Exec's Sub-list Based on China's Top 100 Innovative Pharmaceutical Enterprises (referred to as "Innovative 100 Strong") Focuses on Companies Representing the Potential of China's Pharmaceutical Innovation. They Are the Important Reserve Forces for the Transformation and Upgrading of China's Pharmaceutical Industry and the Enhancement of Industrial Competitiveness.
Four portfolio companies of YuanSheng Ventures proudly made the list: Bo sheng ji medicine science and technology (suzhou) co., LTD, WatWaterstone Pharmaceuticals, Juncell Therapeutics, and ArkBio.
END
About YuanSheng Venture Capital
Yuansheng Venture CapitalIt is an investment institution focused on the early and growth-stage healthcare sector, based in Suzhou BioBAY with a global reach. It has already invested in over 200 outstanding enterprises in the life sciences and healthcare field, covering areas such as new drug development, medical devices, in vitro diagnostics, precision medicine, and more.Future Medical TechnologyIn four major directions, substantial investment returns have been achieved, with 20 enterprises already listed on capital markets such as the Hong Kong Stock Exchange and the Sci-Tech Innovation Board. OrbiMed has repeatedly been ranked among the Top 10 venture capital funds in China's healthcare sector and recognized as one of the most active healthcare investment institutions in China. With a team of seasoned professional investors and a world-class scientific advisory board, OrbiMed possesses extensive experience in entrepreneurship, venture capital, and corporate operations within the biopharmaceutical industry. Leveraging professionalism, dedication, and abundant industry resources, we are committed to becoming one of the most successful healthcare and pharmaceutical venture capital funds in China.
